Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
KdT Ventures
AddedFeb 13, 2024
UpdatedJul 16, 2026
KdT Ventures

KdT Ventures

Operating

KdT Ventures: A seed-stage venture firm, transforming ideas into impactful tech-science companies.

Location
Austin, TX, US
Founded
2017
Firm
Compare
Portfolio
Fundraising
Employees
Website

Investments

Motif Neurotech
Motif Neurotech

Total Raised

$18.9M

Rounds

2

Series A$18.8MJanuary 2024
Zymochem
Zymochem

Total Raised

$29.6M

Rounds

6

Series A$21MJanuary 2024
Seed$4MDecember 2021
Aperiam Bio
Aperiam Bio

Total Raised

$12.7M

Rounds

2

Seed$9MNovember 2023
Surge Therapeutics
Surge Therapeutics

Total Raised

$58M

Rounds

2

Series B$32MJuly 2023
Andes
Andes

Total Raised

$56M

Rounds

7

Series A$15MMarch 2023
Series A$15MAugust 2021
Dimension Inx
Dimension Inx

Total Raised

$17.7M

Rounds

4

Series A$12MFebruary 2023
Asimov
Asimov

Total Raised

$205M

Rounds

4

Series B$175MJanuary 2023
Onc.AI
Onc.AI

Total Raised

$31M

Rounds

2

Series A$25MJanuary 2023
54Gene
54Gene
Acquired

Total Raised

$94.7M

Rounds

8

Convertible Note$50MOctober 2022
Series B$25MSeptember 2021
Equii
Equii

Total Raised

$6M

Rounds

1

Seed$6MSeptember 2022
Tavros Therapeutics
Tavros Therapeutics

Total Raised

$28M

Rounds

3

Seed$7.5MSeptember 2022
Canaery
Canaery

Total Raised

$4M

Rounds

5

Seed$4MJuly 2022
Faeth Therapeutics
Faeth Therapeutics

Total Raised

$67M

Rounds

4

Series A$47MJune 2022
Seed$20MJanuary 2022
Terray Therapeutics
Terray Therapeutics

Total Raised

$80M

Rounds

5

Series A$60MFebruary 2022
Marigold Health
Marigold Health

Total Raised

$21.5M

Rounds

12

Seed$6MFebruary 2022
Green Eye Technology
Green Eye Technology

Total Raised

$31M

Rounds

6

Series A$22MDecember 2021
Parthenon Therapeutics
Parthenon Therapeutics

Total Raised

$65M

Rounds

1

Series A$65MNovember 2021
Unravel Biosciences
Unravel Biosciences

Total Raised

$3.3M

Rounds

5

Pre-Seed$1.6MOctober 2021
Debut
Debut

Total Raised

$66.2M

Rounds

4

Series A$22.6MAugust 2021
Modulus Therapeutics
Modulus Therapeutics

Total Raised

$3.5M

Rounds

1

Seed$3.5MJuly 2021
Xilis
Xilis

Total Raised

$92M

Rounds

5

Series A$70MJuly 2021